z-logo
open-access-imgOpen Access
Metformin improves the weight reduction effect of mazindol in prediabetic obese Mexican subjects
Author(s) -
Federico Argüelles-Tello,
Ashuin Kammar-García,
Cristian Adolfo Trejo-Jasso,
Juan Carlos Huerta-Cruz,
Lina Marcela Barranco-Garduño,
Héctor Isaac Rocha-González,
Juan Gerardo Reyes-García
Publication year - 2022
Publication title -
international journal of clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.363
H-Index - 67
ISSN - 0946-1965
DOI - 10.5414/cp204180
Subject(s) - mazindol , metformin , medicine , glycemic , endocrinology , glycated hemoglobin , type 2 diabetes , prediabetes , diabetes mellitus , weight loss , obesity , insulin , dopamine
Obesity is the strongest risk factor for type 2 diabetes (T2D). We aimed to explore 7% weight reduction rates of mazindol alone or combined with metformin in non-diabetic obese Mexican subjects who had additional risk factors for T2D.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here